OA20.02 HIV-resistant dual CD28/4-1BB costimulated CAR T cells mitigate HIV pathogenesis in humanized miceOral Abstract SessionCellular immunity
OA20.05 HIV-1 infection and the control of viral replication are associated with greater expression of interleukin-21 receptor on CD8+ T cellsOral Abstract SessionCellular immunity
PE03.01 Breadth of CD8 T-cell mediated inhibition of HIV-1 replication correlates with breadth of epitope recognition mapped with a comprehensive Gag, Nef, Env and Pol potential T-cell Epitope (PTE) peptide setE-posterCellular immunity
PE03.03 Incidence, clinical spectrum, risk factors and outcome of immune reconstitution inflammatory syndrome (IRIS) among HIV patients on highly active anti-retroviral therapy (HAART) in the south west region of CameroonE-posterCellular immunity
PE03.04LB Infection with a highly Gag pre-adapted virus broadens the proteins targeted by CTLs during acute HIV infectionE-posterCellular immunity
PU03.01 Generation of HIV-specific CD4 and CD8 T-cell clones for use in HIV viral inhibition assaysPublication OnlyCellular immunity
HY01.01LB VRC01 antibody prevention of HIVOral Abstract SessionClinical trial results
HY01.02LB Long acting injectable cabotegravir is safe and effective in preventing HIV infection in cisgender women: interim results from HPTN 084Oral Abstract SessionClinical trial results
OA03.01 Safety and single-dose pharmacokinetics of VRC07-523LS administered via different routes and dosesOral Abstract SessionClinical trial results
OA04.05LB Trial design, enrollment status, demographics, and pharmacokinetics (PK) data from a blinded interim analysis from a phase 2a trial of Islatravir once monthly (QM) for HIV pre-exposure prophylaxis (PrEP)Oral Abstract SessionClinical trial results
seek-warrow-warrow-eseek-e111 - 120 of 444 items